Sonoma Pharmaceuticals Gets Approvals from Singapore

Sonoma Pharmaceuticals (NASDAQ:SNOA) received two new regulatory approvals from the Singapore government for the company’s Microcyn Technology-based hydrogels.
As quoted in the press release:

The first approval is for EZyma™ Hydrogel, which is intended for the management of itching dryness, redness, burning and pain associated with atopic dermatitis.  The second clearance is for ScarLess™ Hydrogel to be used as an adjuvant in the wound healing process as well for managing and reducing new and existing hypertrophic and keloid scars.
“We have seen these dermatological hydrogels successfully address both atopic dermatitis and management of scars around the globe,” said Bruce Thornton, Sonoma Pharmaceuticals vice president of international sales.  “So we are most pleased to be able to bring these innovative technologies to dermatologists and plastic surgeons in Singapore and Malaysia, thus enabling these healthcare professionals to further improve patient outcomes.”
Sonoma’s distribution partner in Singapore, Dyamed Biotech, will launch both products in September 2017.

Click here to read the full press release.

Source: globenewswire.com